Improvement of severe alopecia areata after 9‐month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis

The Journal of DermatologyEarly View LETTER TO THE EDITOR Improvement of severe alopecia areata after 9-month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis Hideaki Uchida, Hideaki Uchida Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorMasahiro Kamata, Corresponding Author Masahiro Kamata [email protected] orcid.org/0000-0003-0976-4982 Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan Correspondence Masahiro Kamata, Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. Email: [email protected]Search for more papers by this authorAyu Watanabe, Ayu Watanabe Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorMakoto Ito, Makoto Ito Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorSaki Fukaya, Saki Fukaya Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorKotaro Hayashi, Kotaro Hayashi Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorAtsuko Fukuyasu, Atsuko Fukuyasu Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorTakamitsu Tanaka, Takamitsu Tanaka Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorTakeko Ishikawa, Takeko Ishikawa Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorYayoi Tada, Yayoi Tada orcid.org/0000-0003-3743-135X Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this author Hideaki Uchida, Hideaki Uchida Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorMasahiro Kamata, Corresponding Author Masahiro Kamata [email protected] orcid.org/0000-0003-0976-4982 Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan Correspondence Masahiro Kamata, Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. Email: [email protected]Search for more papers by this authorAyu Watanabe, Ayu Watanabe Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorMakoto Ito, Makoto Ito Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorSaki Fukaya, Saki Fukaya Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorKotaro Hayashi, Kotaro Hayashi Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorAtsuko Fukuyasu, Atsuko Fukuyasu Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorTakamitsu Tanaka, Takamitsu Tanaka Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorTakeko Ishikawa, Takeko Ishikawa Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this authorYayoi Tada, Yayoi Tada orcid.org/0000-0003-3743-135X Department of Dermatology, Teikyo University School of Medicine, Tokyo, JapanSearch for more papers by this author First published: 23 July 2023 https://doi.org/10.1111/1346-8138.16893Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1King B, Ohyama M, Kwon O, et al. Two phase 3 trials of Baricitinib for alopecia areata. N Engl J Med. 2022; 386: 1687–99. 2Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020; 183: 242–55. 3Reich K, Kabashima K, Peris K, et al. Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020; 156: 1333–43. 4Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021; 80: 865–75. 5Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of Baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023; 24: 443–51. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation